A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment
Latest Information Update: 22 Feb 2025
At a glance
- Drugs Lumateperone (Primary)
- Indications Generalised anxiety disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Intra-Cellular Therapies
Most Recent Events
- 22 Nov 2024 Planned End Date changed from 1 Jan 2027 to 1 Jun 2027.
- 22 Nov 2024 Planned primary completion date changed from 1 Dec 2026 to 1 Jun 2027.
- 01 Jul 2024 Status changed from planning to recruiting.